Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Completed × Dosage Forms × Clear all

Phase

Phase NA 3 Phase 3 3 Phase 2 3 Phase 1 3 Phase 4 1 Phase 2/3 1 Phase 1/2 1

Status

Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 109 Gemcitabine 104 Paclitaxel 102 Radiotherapy 96 Carboplatin 91 pembrolizumab 90 Cisplatin 86 Nivolumab 77 Docetaxel 77 Rituximab 67 Lenalidomide 62 Cytarabine 54 Bevacizumab 54 Etoposide 53 Peripheral Blood Stem Cell Transplantation 52 Dexamethasone 52 Fluorouracil 50 Filgrastim 50 Capecitabine 50 fludarabine phosphate 49 Temozolomide 49 Oxaliplatin 46 Doxorubicin 45 Prednisone 44 Irinotecan 44 Everolimus 44 Cetuximab 43 Erlotinib Hydrochloride 42 Sorafenib 41 Melphalan 41

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03593187 2025-11-20

GENHIV

Assistance Publique - Hôpitaux de Paris

Phase 1/2 Completed

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡